U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07591649) titled 'Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT' on May 11.
Brief Summary: This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy [cyclophosphamide (CY)/fludarabine (FLU)] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Relaps...